{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:57:51Z","timestamp":1791053871761,"version":"4.1.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","award":["K43 TW010695"],"award-info":[{"award-number":["K43 TW010695"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["K24 MH114732"],"award-info":[{"award-number":["K24 MH114732"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40265-020-01419-4","type":"journal-article","created":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T16:02:52Z","timestamp":1602345772000},"page":"1881-1888","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Lamivudine\/Tenofovir Disoproxil Fumarate is an Appropriate PrEP Regimen"],"prefix":"10.1007","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6646-6733","authenticated-orcid":false,"given":"Andrew","family":"Mujugira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared M.","family":"Baeten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Hodges-Mameletzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica E.","family":"Haberer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,10]]},"reference":[{"key":"1419_CR1","unstructured":"Joint United Nations Programme on HIV\/AIDS (2019). UNAIDS Data 2019. Available from: https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/2019-UNAIDS-data_en.pdf. Accessed 20 Feb 2020."},{"key":"1419_CR2","unstructured":"Joint United Nations Programme on HIV\/AIDS (2018). Miles to go\u2014closing gaps, breaking barriers, righting injustices. Available from: http:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/miles-to-go_en.pdf. Accessed 20 Feb 2020"},{"issue":"3","key":"1419_CR3","first-page":"65","volume":"60","author":"Centers for Disease Control and Prevention (CDC)","year":"2011","unstructured":"MMWR Morbidity and mortality weekly report. Centers for Disease Control and Prevention (CDC). Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. 2011;60(3):65\u20138.","journal-title":"MMWR Morbidity and mortality weekly report."},{"key":"1419_CR4","unstructured":"MMWR Morbidity and mortality weekly report. Centers for Disease Control and Prevention (CDC). Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. 2012;61(31):586\u20139."},{"issue":"27","key":"1419_CR5","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","volume":"363","author":"RM Grant","year":"2010","unstructured":"Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587\u201399. https:\/\/doi.org\/10.1056\/NEJMoa1011205.","journal-title":"N Engl J Med"},{"issue":"5","key":"1419_CR6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1108524","volume":"367","author":"JMDD Baeten","year":"2012","unstructured":"Baeten JMDD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399\u2013410. https:\/\/doi.org\/10.1056\/NEJMoa1108524.","journal-title":"N Engl J Med"},{"issue":"5","key":"1419_CR7","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1056\/NEJMoa1110711","volume":"367","author":"MC Thigpen","year":"2012","unstructured":"Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1110711.","journal-title":"N Engl J Med"},{"issue":"23","key":"1419_CR8","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","volume":"373","author":"JM Molina","year":"2015","unstructured":"Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1506273.","journal-title":"N Engl J Med"},{"issue":"10013","key":"1419_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/s0140-6736(15)00056-2","volume":"387","author":"S McCormack","year":"2016","unstructured":"McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53\u201360. https:\/\/doi.org\/10.1016\/s0140-6736(15)00056-2.","journal-title":"Lancet"},{"issue":"12","key":"1419_CR10","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1097\/qad.0000000000001145","volume":"30","author":"VA Fonner","year":"2016","unstructured":"Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O'Reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30(12):1973\u201383. https:\/\/doi.org\/10.1097\/qad.0000000000001145.","journal-title":"AIDS"},{"key":"1419_CR11","unstructured":"US Food and Drug Administration (2014). Truvada for PrEP fact sheet: Ensuring safe and proper use. Available from: https:\/\/www.fda.gov\/media\/83586\/download. Accessed 20 Feb 2020."},{"key":"1419_CR12","unstructured":"World Health Organization (2015). Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV.  Available from: http:\/\/www.who.int\/hiv\/pub\/guidelines\/earlyrelease-arv\/en\/. Accessed 9 Nov 2019."},{"key":"1419_CR13","unstructured":"AVAC (2018). PrEPWatch. Country Updates. Available from: https:\/\/www.prepwatch.org\/in-practice\/country-updates\/. Accessed 9 Nov 2019."},{"key":"1419_CR14","unstructured":"World Health Organization (2017). Technical Update on Appropriate Medicines Options for Pre-Exposure Prophylaxis. Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/273934\/WHO-CDS-HIV-18.22-eng.pdf?ua=1. Accessed 9 Nov 2019."},{"key":"1419_CR15","unstructured":"European Medicines Agency (2016). Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP). Available from: https:\/\/www.ema.europa.eu\/news\/first-medicine-hiv-pre-exposure-prophylaxis-recommended-approval-eu. Accessed 20 Feb 2020."},{"key":"1419_CR16","unstructured":"World Health Organization (2018). WHO essential medicines and health products: annual report 2017: towards access 2030 (No. WHO\/EMP\/2018.01). Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/272972. Accessed 20 Feb 2020."},{"issue":"4","key":"1419_CR17","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/coh.0000000000000377","volume":"12","author":"N Ford","year":"2017","unstructured":"Ford N, Vitoria M, Doherty M, Gray A. Candidates for inclusion in a universal antiretroviral regimen: are lamivudine and emtricitabine interchangeable? Curr Opin HIV AIDS. 2017;12(4):334\u20138. https:\/\/doi.org\/10.1097\/coh.0000000000000377.","journal-title":"Curr Opin HIV AIDS"},{"issue":"3","key":"1419_CR18","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1128\/aac.05599-11","volume":"56","author":"LJ Else","year":"2012","unstructured":"Else LJ, Jackson A, Puls R, Hill A, Fahey P, Lin E, et al. Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. Antimicrob Agents Chemother. 2012;56(3):1427\u201333. https:\/\/doi.org\/10.1128\/aac.05599-11.","journal-title":"Antimicrob Agents Chemother"},{"key":"1419_CR19","doi-asserted-by":"publisher","unstructured":"Wang LH, Begley J, St Claire RL, 3rd, Harris J, Wakeford C, Rousseau FS. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. AIDS Res Human Retrovir. 2004;20(11):1173\u201382. https:\/\/doi.org\/10.1089\/aid.2004.20.1173.","DOI":"10.1089\/aid.2004.20.1173"},{"issue":"1","key":"1419_CR20","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1128\/aac.48.1.176-182.2004","volume":"48","author":"GJ Yuen","year":"2004","unstructured":"Yuen GJ, Lou Y, Bumgarner NF, Bishop JP, Smith GA, Otto VR, et al. Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. Antimicrob Agents Chemother. 2004;48(1):176\u201382. https:\/\/doi.org\/10.1128\/aac.48.1.176-182.2004.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"1419_CR21","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1128\/aac.06337-11","volume":"56","author":"JE Rower","year":"2012","unstructured":"Rower JE, Meditz A, Gardner EM, Lichtenstein K, Predhomme J, Bushman LR, et al. Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine. Antimicrob Agents Chemother. 2012;56(6):3011\u20139. https:\/\/doi.org\/10.1128\/aac.06337-11.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1419_CR22","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/cid\/ciu916","volume":"60","author":"SM Seifert","year":"2015","unstructured":"Seifert SM, Glidden DV, Meditz AL, Castillo-Mancilla JR, Gardner EM, Predhomme JA, et al. Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men. Clin Infect Dis. 2015;60(5):804\u201310. https:\/\/doi.org\/10.1093\/cid\/ciu916.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"1419_CR23","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1128\/aac.44.11.3097-3100.2000","volume":"44","author":"JF Rodriguez","year":"2000","unstructured":"Rodriguez JF, Rodriguez JL, Santana J, Garc\u00eda H, Rosario O. Simultaneous quantitation of intracellular zidovudine and lamivudine triphosphates in human immunodeficiency virus-infected individuals. Antimicrob Agents Chemother. 2000;44(11):3097\u2013100. https:\/\/doi.org\/10.1128\/aac.44.11.3097-3100.2000.","journal-title":"Antimicrob Agents Chemother"},{"issue":"16","key":"1419_CR24","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1097\/00002030-199911120-00006","volume":"13","author":"KH Moore","year":"1999","unstructured":"Moore KH, Barrett JE, Shaw S, Pakes GE, Churchus R, Kapoor A, et al. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. Aids. 1999;13(16):2239\u201350. https:\/\/doi.org\/10.1097\/00002030-199911120-00006.","journal-title":"Aids"},{"issue":"7","key":"1419_CR25","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1128\/aac.01487-10","volume":"55","author":"C Bazzoli","year":"2011","unstructured":"Bazzoli C, B\u00e9nech H, Rey E, Retout S, Salmon D, Duval X, et al. Joint population pharmacokinetic analysis of zidovudine, lamivudine, and their active intracellular metabolites in HIV patients. Antimicrob Agents Chemother. 2011;55(7):3423\u201331. https:\/\/doi.org\/10.1128\/aac.01487-10.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"1419_CR26","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1128\/aac.01441-15","volume":"59","author":"L Dickinson","year":"2015","unstructured":"Dickinson L, Yapa HM, Jackson A, Moyle G, Else L, Amara A, et al. Plasma tenofovir, emtricitabine, and rilpivirine and intracellular tenofovir diphosphate and emtricitabine triphosphate pharmacokinetics following drug intake cessation. Antimicrob Agents Chemother. 2015;59(10):6080\u20136. https:\/\/doi.org\/10.1128\/aac.01441-15.","journal-title":"Antimicrob Agents Chemother"},{"issue":"15","key":"1419_CR27","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1097\/00002030-200310170-00003","volume":"17","author":"PL Anderson","year":"2003","unstructured":"Anderson PL, Kakuda TN, Kawle S, Fletcher CV. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. Aids. 2003;17(15):2159\u201368. https:\/\/doi.org\/10.1097\/00002030-200310170-00003.","journal-title":"Aids"},{"issue":"9","key":"1419_CR28","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2165\/00003088-200140090-00005","volume":"40","author":"R Bruno","year":"2001","unstructured":"Bruno R, Regazzi MB, Ciappina V, Villani P, Sacchi P, Montagna M, et al. Comparison of the plasma pharmacokinetics of lamivudine during twice and once daily administration in patients with HIV. Clin Pharmacokinet. 2001;40(9):695\u2013700.","journal-title":"Clin Pharmacokinet"},{"key":"1419_CR29","doi-asserted-by":"crossref","unstructured":"Schinazi RF. Assessment of the relative potency of emtricitabine and lamivudine. J Acquir Immune Defic Syndr. 2003;34(2):243\u20135 (author reply 5\u20136).","DOI":"10.1097\/00126334-200310010-00017"},{"issue":"2","key":"1419_CR30","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jpba.2011.05.039","volume":"56","author":"LR Bushman","year":"2011","unstructured":"Bushman LR, Kiser JJ, Rower JE, Klein B, Zheng JH, Ray ML, et al. Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS\/MS detection. J Pharm Biomed Anal. 2011;56(2):390\u2013401. https:\/\/doi.org\/10.1016\/j.jpba.2011.05.039.","journal-title":"J Pharm Biomed Anal"},{"key":"1419_CR31","unstructured":"Maserati R. Differentiating emtricitabine (FTC) from lamivudine (3TC): what a \u201cfine-tuning\u201d of antiretroviral therapy might entail. Available from: http:\/\/win.mnlpublimed.com\/public\/HA10-A04.pdf.  Accessed 11 Sept 2020."},{"issue":"14","key":"1419_CR32","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1097\/QAD.0b013e328270385a","volume":"21","author":"JB Dumond","year":"2007","unstructured":"Dumond JB, Yeh RF, Patterson KB, Corbett AH, Jung BH, Rezk NL, et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. Aids. 2007;21(14):1899\u2013907. https:\/\/doi.org\/10.1097\/QAD.0b013e328270385a.","journal-title":"Aids"},{"issue":"2","key":"1419_CR33","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/QAI.0b013e31816de21e","volume":"48","author":"JB Dumond","year":"2008","unstructured":"Dumond JB, Reddy YS, Troiani L, Rodriguez JF, Bridges AS, Fiscus SA, et al. Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men. J Acquir Immune Defic Syndr. 2008;48(2):156\u201362. https:\/\/doi.org\/10.1097\/QAI.0b013e31816de21e.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"1419_CR34","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1089\/aid.2015.0182","volume":"32","author":"CW Hendrix","year":"2016","unstructured":"Hendrix CW, Andrade A, Bumpus NN, Kashuba AD, Marzinke MA, Moore A, et al. Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066). AIDS Res Hum Retroviruses. 2016;32(1):32\u2013433. https:\/\/doi.org\/10.1089\/aid.2015.0182.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"11","key":"1419_CR35","doi-asserted-by":"publisher","first-page":"6800","DOI":"10.1128\/aac.01517-15","volume":"59","author":"E Valade","year":"2015","unstructured":"Valade E, Tr\u00e9luyer JM, Illamola SM, Bouazza N, Foissac F, De Sousa MM, et al. Emtricitabine seminal plasma and blood plasma population pharmacokinetics in HIV-infected men in the EVARIST ANRS-EP 49 study. Antimicrob Agents Chemother. 2015;59(11):6800\u20136. https:\/\/doi.org\/10.1128\/aac.01517-15.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10\u201311","key":"1419_CR36","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1089\/aid.2016.0008","volume":"32","author":"SM Seifert","year":"2016","unstructured":"Seifert SM, Chen X, Meditz AL, Castillo-Mancilla JR, Gardner EM, Predhomme JA, et al. Intracellular tenofovir and emtricitabine anabolites in genital, rectal, and blood compartments from first dose to steady state. AIDS Res Hum Retrovir. 2016;32(10\u201311):981\u201391. https:\/\/doi.org\/10.1089\/aid.2016.0008.","journal-title":"AIDS Res Hum Retrovir"},{"key":"1419_CR37","doi-asserted-by":"publisher","unstructured":"Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med. 2011;3(112):112re4. https:\/\/doi.org\/10.1126\/scitranslmed.3003174.","DOI":"10.1126\/scitranslmed.3003174"},{"issue":"3","key":"1419_CR38","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0163-7258(99)00062-5","volume":"85","author":"J Zemlicka","year":"2000","unstructured":"Zemlicka J. Enantioselectivity of the antiviral effects of nucleoside analogues. Pharmacol Ther. 2000;85(3):251\u201366.","journal-title":"Pharmacol Ther"},{"issue":"6","key":"1419_CR39","first-page":"1624","volume":"62","author":"JY Liou","year":"2002","unstructured":"Liou JY, Dutschman GE, Lam W, Jiang Z, Cheng YC. Characterization of human UMP\/CMP kinase and its phosphorylation of d- and l-form deoxycytidine analogue monophosphates. Cancer Res. 2002;62(6):1624\u201331.","journal-title":"Cancer Res"},{"key":"1419_CR40","unstructured":"World Health Organization (2012). Technical update on treatment optimization: pharmacological equivalence and clinical interchangeability of\nlamivudine and emtricitabine: a review of current literature. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/70936. Accessed 20 Feb 2020."},{"issue":"11","key":"1419_CR41","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1086\/379667","volume":"188","author":"FS Rousseau","year":"2003","unstructured":"Rousseau FS, Wakeford C, Mommeja-Marin H, Sanne I, Moxham C, Harris J, et al. Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients. J Infect Dis. 2003;188(11):1652\u20138. https:\/\/doi.org\/10.1086\/379667.","journal-title":"J Infect Dis"},{"issue":"11","key":"1419_CR42","doi-asserted-by":"publisher","first-page":"e79981","DOI":"10.1371\/journal.pone.0079981","volume":"8","author":"N Ford","year":"2013","unstructured":"Ford N, Shubber Z, Hill A, Vitoria M, Doherty M, Mills EJ, et al. Comparative efficacy of Lamivudine and emtricitabine: a systematic review and meta-analysis of randomized trials. PLoS ONE. 2013;8(11):e79981. https:\/\/doi.org\/10.1371\/journal.pone.0079981.","journal-title":"PLoS ONE"},{"key":"1419_CR43","unstructured":"World Health Organization (2002). Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach: executive\nsummary. Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/42514\/9241545674.pdf. Accessed 20 Feb 2020."},{"key":"1419_CR44","unstructured":"World Health Organization (2016). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/208825\/9789241549684_eng.pdf. Accessed 20 Feb 2020."},{"issue":"11","key":"1419_CR45","doi-asserted-by":"publisher","first-page":"e454","DOI":"10.1371\/journal.pmed.0030454","volume":"3","author":"I Derdelinckx","year":"2006","unstructured":"Derdelinckx I, Wainberg MA, Lange JM, Hill A, Halima Y, Boucher CA. Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection. PLoS Med. 2006;3(11):e454.","journal-title":"PLoS Med"},{"issue":"10","key":"1419_CR46","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1128\/AAC.37.10.2231","volume":"37","author":"CA Boucher","year":"1993","unstructured":"Boucher CA, Cammack N, Schipper P, Schuurman R, Rouse P, Wainberg MA, et al. High-level resistance to (\u2212) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 1993;37(10):2231\u20134.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"1419_CR47","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1128\/AAC.47.11.3377-3383.2003","volume":"47","author":"K Diallo","year":"2003","unstructured":"Diallo K, Gotte M, Wainberg MA. Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 2003;47(11):3377\u201383.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"1419_CR48","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1128\/CDLI.10.6.979-981.2003","volume":"10","author":"D Turner","year":"2003","unstructured":"Turner D, Brenner B, Wainberg MA. Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1. Clin Diagn Lab Immunol. 2003;10(6):979\u201381.","journal-title":"Clin Diagn Lab Immunol"},{"issue":"2","key":"1419_CR49","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/qai.0000000000001660","volume":"78","author":"R Quercia","year":"2018","unstructured":"Quercia R, Perno CF, Koteff J, Moore K, McCoig C, St Clair M, et al. Twenty-five years of lamivudine: current and future use for the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2018;78(2):125\u201335. https:\/\/doi.org\/10.1097\/qai.0000000000001660.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"1419_CR50","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1128\/AAC.47.11.3478-3484.2003","volume":"47","author":"K Wolf","year":"2003","unstructured":"Wolf K, Walter H, Beerenwinkel N, Keulen W, Kaiser R, Hoffmann D, et al. Tenofovir resistance and resensitization. Antimicrob Agents Chemother. 2003;47(11):3478\u201384.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5224","key":"1419_CR51","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1126\/science.7542804","volume":"269","author":"BA Larder","year":"1995","unstructured":"Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science. 1995;269(5224):696\u20139.","journal-title":"Science"},{"issue":"6","key":"1419_CR52","doi-asserted-by":"publisher","first-page":"831","DOI":"10.3851\/imp2650","volume":"18","author":"D Pillay","year":"2013","unstructured":"Pillay D, Albert J, Bertagnolio S, Boucher C, Brun-Vezinet F, Clotet B, et al. Implications of HIV drug resistance on first- and second-line therapies in resource-limited settings: report from a workshop organized by the Collaborative HIV and Anti-HIV Drug Resistance Network. Antiviral Therapy. 2013;18(6):831\u20136. https:\/\/doi.org\/10.3851\/imp2650.","journal-title":"Antiviral Therapy"},{"key":"1419_CR53","unstructured":"World Health Organization (2017). Global Price Reporting Mechanism for HIV, tuberculosis and malaria. Available from: http:\/\/www.who.int\/hiv\/amds\/gprm\/en\/. Accessed 20 Feb 2020."},{"key":"1419_CR54","doi-asserted-by":"publisher","unstructured":"Massud I, Sykes C, Cong ME, Ellis S, Kelly K, Heneine W et al. Pharmacokinetic profile of lamivudine (3TC) in macaques and relative drug exposure in rectal and vaginal tissues. abstracts of the HIV research for prevention meeting, HIVR4P, 17\u201320 October, 2016, Chicago, USA. AIDS Res Human Retrovir. 2016;32(S1):1\u2013409. https:\/\/doi.org\/10.1089\/aid.2016.5000.abstracts.","DOI":"10.1089\/aid.2016.5000.abstracts"},{"key":"1419_CR55","unstructured":"Vyankandondera J, Luchters S, Hassink E, Pakker N, Mmiro F, Okong P et al., editors. Reducing risk of HIV-1 transmission from mother to infant through breastfeeding using antiretroviral prophylaxis in infants (SIMBA-study). In: 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris; 2003."},{"issue":"3","key":"1419_CR56","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/QAI.0b013e31816e395c","volume":"48","author":"C Kilewo","year":"2008","unstructured":"Kilewo C, Karlsson K, Massawe A, Lyamuya E, Swai A, Mhalu F, et al. Prevention of mother-to-child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study. J Acquir Immune Defic Syndr. 2008;48(3):315\u201323. https:\/\/doi.org\/10.1097\/QAI.0b013e31816e395c.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"1419_CR57","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/s1473-3099(10)70288-7","volume":"11","author":"I de Vincenzi","year":"2011","unstructured":"de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis. 2011;11(3):171\u201380. https:\/\/doi.org\/10.1016\/s1473-3099(10)70288-7.","journal-title":"Lancet Infect Dis"},{"issue":"10018","key":"1419_CR58","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/s0140-6736(15)00984-8","volume":"387","author":"N Nagot","year":"2016","unstructured":"Nagot N, Kankasa C, Tumwine JK, Meda N, Hofmeyr GJ, Vallo R, et al. Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial. Lancet. 2016;387(10018):566\u201373. https:\/\/doi.org\/10.1016\/s0140-6736(15)00984-8.","journal-title":"Lancet"},{"key":"1419_CR59","unstructured":"Mancuzo AV, Carvalho LV, Carvalho GC et al. Evaluation of the acceptability, feasibility, safety and adherence to pre-exposure prophylaxis (PrEP) for\nHIV prevention in men who have sex with men (MSM): Phase 1 study (submitted abstract) [cited in\nhttps:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/273934\/WHO-CDS-HIV-18.22-eng.pdf?ua=1]."},{"key":"1419_CR60","volume-title":"TDF\/3TC for PrEP: the rationale and the evidence","author":"I Hodges-Mameletzis","year":"2019","unstructured":"Hodges-Mameletzis I. TDF\/3TC for PrEP: the rationale and the evidence. Geneva: World Health Organization; 2019."},{"issue":"11","key":"1419_CR61","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/s1473-3099(14)70937-5","volume":"14","author":"JM Baeten","year":"2014","unstructured":"Baeten JM, Donnell D, Mugo NR, Ndase P, Thomas KK, Campbell JD, et al. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. Lancet Infect Dis. 2014;14(11):1055\u201364. https:\/\/doi.org\/10.1016\/s1473-3099(14)70937-5.","journal-title":"Lancet Infect Dis"},{"key":"1419_CR62","unstructured":"PEPFAR. Recommendations on the Use of PrEP for All Populations. PEPFAR Scientific Advisory Board (SAB). 2015."},{"key":"1419_CR63","unstructured":"European AIDS Clinical Society Guidelines (Version 9.0, October 2017). Available from: https:\/\/www.eacsociety.org\/files\/guidelines_9.0-english.pdf. Accessed  20 Feb 2020."},{"issue":"6","key":"1419_CR64","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1071\/sh18125","volume":"15","author":"I Hodges-Mameletzis","year":"2018","unstructured":"Hodges-Mameletzis I, Dalal S, Msimanga-Radebe B, Rodolph M, Baggaley R. Going global: the adoption of the World Health Organization's enabling recommendation on oral pre-exposure prophylaxis for HIV. Sexual health. 2018;15(6):489\u2013500. https:\/\/doi.org\/10.1071\/sh18125.","journal-title":"Sexual health"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01419-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-020-01419-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01419-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:42:19Z","timestamp":1633912939000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-020-01419-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,10]]},"references-count":64,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1419"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01419-4","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,10]]},"assertion":[{"value":"10 October 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported through research grants from National Institutes of Health (research grant number K43 TW010695 (AM) and K24 mentor award MH114732 (JEH)). This paper represents the opinions of the authors and does not necessarily represent the official views of the National Institutes of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"JMB served as an advisor for Gilead Sciences, Janssen, and Merck. JEH is a consultant for Merck. AM received donated FTC\/TDF from Gilead Sciences for an investigator-sponsored study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"AM, JMB, and JEH conceptualized the paper. AM wrote the first draft along with JEH. IHM, JMB, JEH, and AM reviewed drafts and provided substantial edits. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}